



## UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

May 3, 2022

*Conference Call and Webcast Scheduled for Tuesday, May 10, 2022 at 10:00 AM ET*

PRINCETON, N.J.--(BUSINESS WIRE)--May 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2022 financial results on Tuesday, May 10, 2022, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

### Audio Webcast

The webcast will be made available on the Investors section of the Company's website at <http://investors.urogen.com>. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

### Dial-In Information

Live (U.S. / Canada): (855) 765-5685

Live (International): (615) 247-5916

Confirmation number: 6687048

### About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit [www.urogen.com](http://www.urogen.com) to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220503005426/en/): <https://www.businesswire.com/news/home/20220503005426/en/>

### INVESTORS:

Vincent Perrone

Senior Director, Investor Relations

[vincent.perrone@urogen.com](mailto:vincent.perrone@urogen.com)

609-460-3588 ext. 1093

### MEDIA:

Cindy Romano

Director, Corporate Communications

[cindy.romano@urogen.com](mailto:cindy.romano@urogen.com)

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.